Sanaria's primary mission is to develop and commercialize whole-parasite sporozoite vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the malaria parasite responsible for more than 95% of malaria associated severe illness and death world-wide and the malaria parasite for which there is the most significant drug resistance.
Quantities of mosquitoes.
Live, aseptic and non-aseptic P. falciparum infected mosquitoes. These well-characterized mosquitoes are for experimentally challenging volunteers in studies assessing malaria vaccines and drugs and for laboratory-based research.
Monoclonal and/or polyclonal antibodies are available against PfCelTOS, PfEXP-1, PfCSP, PvCSP, and Pf sporozoites.
The following purified recombinant proteins are available: PfCSP, PvCSP, PfCelTOS, PvCelTOS, PyCelTOS, PfSSP2/TRAP, PfLSA-1, PfEXP-1, PfEBA-175, PyCSP.
Assessment of the effects of antibodies and drugs on the capacity of P. falciparum and P. vivax sporozoites to invade and develop in hepatocytes (inhibition of liver stage development assay), and of P. falciparum gametocytes to develop to oocysts and sporozoites in mosquitoes (transmission blocking assay). Assessment of antibodies to all life cycle stages of Plasmodium species by immunofluoresence assays and to selected antigens by ELISA.
Sanaria will manufacture Plasmodium species reagents to meet your specifications:
Plasmodium Reagent Slides
Plasmodium falciparum Sporozoite Reagents
Sanaria Inc. has not received any reviews.
Sanaria Inc. has not received any endorsements.